Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in Refractory Multiple Myeloma
NCT02971410Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simvastatin in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Primary endpoints: Change in free light chain ratios up to 126 Days and Change in M-protein level up to 126 Days. Planned start Apr 2017; status: withdrawn.
02
Drugs
simvastatin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02971410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971410.